Apos Medical Assets—a global medical device company operating in the United States, the United Kingdom, Israel and Singapore—announced today that it raised $11 million in a new round of funding. The funding comes mainly from the current Moon investor, insiders and directors of the company.
“Apos Therapy has entered an exciting phase with a double-digit quarter over quarter growth and a management team focused on increasing distribution, paying coverage and bringing enhanced products and capabilities to the market,” said Joseph Mark, Chairman of the Board of Directors.
This new funding round will be used to support a rapid expansion into new territories with increased sales capabilities, account management expertise and consumer marketing expertise. Funding will also support R&D in the next generation of Apos Therapy devices with built-in sensor technology that delivers real-time biometric data to the cloud, upgraded customer support clinical tracking systems, behavior modification technology and enhanced business intelligence to manage the company’s increasingly sophisticated data sets.
“This funding round continues to validate our success in creating value for payers, new treatment options for providers, and solutions for patients with musculoskeletal pain Apos Therapy reduces pain, improves function and is a potential alternative to invasive surgery for people with knee osteoarthritis and is used as part of a healthy lifestyle in patients with chronic back pain and hip pain,” said Apos Medical Assets Ltd, CEO and President Cliff Bleustein. “With the rapid expansion and growth of existing and new territories, including New York, New Jersey, Puerto Rico, California, Massachusetts and Pennsylvania, Apos Therapy® is set to have a breakthrough year in 2020. “That’s right.
Apos Therapy
Apos Therapy is an innovative, FDA-free treatment for knee osteoarthritis and is qualified as a wellness device for use with other musculoskeletal conditions such as lower back pain. Apos Therapy works on biomechanical and neuromuscular levels, combining a patented medical device with a treatment program. Treatment addresses the underlying causes of pain by shifting pressure away from painful areas and providing long-lasting neuromuscular effects by re-educating muscles to a healthier walking pattern, even when not wearing a device.
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Apos%20Medical%20Assets/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
